Translational Oncology · 2021 · 15 citations · 21 references
MedicineMolecular BiologyOncologyCancer ImmunologyChemotherapyMolecular OncologyCancer TranscriptomicsCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint RegulationImmune CheckpointsDna Damage InductionDna Damage Response InhibitorsDna Damage Response ModulationDna Damage Response PathwaysDna Damage Response SignalingPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 Regulation
OBJECTIVES: The immune checkpoint molecule PD-L1 (CD274) is a crucial regulator of the tumor immune response. Its expression has been reported in the therapeutic context in Head and Neck Squamous Cell Carcinoma (HNSCC), but it remains unclear how therapeutically approved molecules regulate PD-L1 expression in HNSCC cells. MATERIALS AND METHODS: Three HNSCC cell lines (BICR6, PE/CA-PJ34 and PE/CA-PJ41) were used to analyze PD-L1 expression by immunoblotting, immunofluorescence and QPCR. Freely-available single cell RNAseq data from HNSCC were also used. RESULTS: 5-Fluorouracil (5-FU) increased the expression of PD-L1 with high efficacy in HNSCC cells. Single cell RNAseq data suggested the specificity of the regulation of PD-L1 in this context. The effect of 5-FU on PD-L1 expression was related to its genotoxic effect and was prevented by extracellular application of thymidine or using a chemical inhibitor of the DNA damage Response kinases ATM/ATR. We found that the effect of 5-FU was additive or synergistic with IFN-γ, the canonical inducer of PD-L1 in epithelial cells. QPCR analysis confirmed this finding and identified JAK-dependent transcriptional activation of PD-L1/CD274 as the underlying mechanism. The induction of PD-L1 by 5-FU was partially prevented by Epidermal Growth Factor Receptor (EGFR) inhibition with cetuximab. CONCLUSION: Our study highlights the specific DNA Damage Response- and JAK- dependent induction of PD-L1 by 5-FU in HNSCC cells. This induction is regulated by the cytokine context and is potentially therapeutically actionable.
21
Large-scale gene function analysis with the PANTHER classification system
Huaiyu Mi, Anushya Muruganujan, John T. Casagrande et al. · Nature Protocols · 2013 · 2.6K citations · Full text
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +11
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen, George A. Crabill, Theresa S. Pritchard et al. · Journal for ImmunoTherapy of Cancer · 2019 · 464 citations · Full text
Medicine, Immunology, Oncology +12